A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
Status:
Completed
Trial end date:
1999-10-01
Target enrollment:
Participant gender:
Summary
The objective of this trial was to investigate the effect of galantamine (an
acetylcholinesterase inhibitor) on heart rate and PR interval (the time it takes for the
heart's electrical impulse to get from the atria to the ventricles) during the administration
of rapidly increasing doses and at the end of a 2-week treatment period with 32 mg per day in
patients with Alzheimer's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.